US76135L5075 - Common Stock
REVELATION BIOSCIENCES INC
NASDAQ:REVB (11/11/2024, 8:00:01 PM)
After market: 0.99 -0.05 (-4.81%)1.04
+0.22 (+26.83%)
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2020-10-08. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).
REVELATION BIOSCIENCES INC
4660 Lajolla Village Drive, Suite 100
San Diego CALIFORNIA
P: 16508003717
Employees: 9
Website: https://www.revbiosciences.com/
Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session.
What's going on in Monday's pre-market session
Curious about the stocks that are showing activity after the closing bell on Friday?
Here you can normally see the latest stock twits on REVB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: